Rankings
▼
Calendar
LGND Q3 2019 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena
LGND
Ligand Pharmaceuticals Incorporated
$4B
Q3 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$25M
-45.7% YoY
Gross Profit
$22M
87.3% margin
Operating Income
-$5M
-20.8% margin
Net Income
-$15M
-61.5% margin
EPS (Diluted)
$-0.81
QoQ Revenue Growth
-0.7%
Cash Flow
Operating Cash Flow
-$6M
Free Cash Flow
-$6M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$1.5B
Total Liabilities
$697M
Stockholders' Equity
$851M
Cash & Equivalents
$1.1B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$25M
$46M
-45.7%
Gross Profit
$22M
$44M
-51.0%
Operating Income
-$5M
$23M
-122.1%
Net Income
-$15M
$67M
-122.6%
← FY 2019
All Quarters
Q4 2019 →